By Nigam Arora & Dr. Natasha Arora
Surgery Centers Are Popular
Surgery centers are popular among investors because they tend to have wide operating margins, durable volume tailwinds, and are asset light.
Surgery Partners (SGRY)
Surgery Partners has more than 200 facilities in 33 states, the largest independent network of surgery centers in the U.S.
Buyout Offer
Surgery Partners has turned down a buyout offer. The reason is that Surgery Partners management believes they can produce more value for shareholders in the long term compared to selling out now for a quick profit.
Buying Opportunity
The drop in SGRY stock on the rejection of a buyout offer is an opportunity for long term investors.
Future Buyout
SGRY remains a buyout target in the future, but a buyout is likely two to three years away.
Buy Zone
For those following the Good Way, the Buy Now rating is *** (To see the locked content, please take a 30 day free trial) to scale in.
For those following the Best Way, the buy zone is $*** – $*** to scale in. It is trading at $19.92 as of this writing.
This is a long term position.
The recommended position size is being increased to ***% – ***%.
In a buyout, the target zone is $37 – $41.
The mental stop zone to reduce the quantity is $*** – $***.
Signal Limited is a Signal(s) with a great record in similar situations but does not meet all of the stringent criteria for a Signal. Typically Signal Limited has higher risk-reward compared to a Signal over the short term.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 1% of the content from our paid services. …TO RECEIVE REMAINING 99%, INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES AND SIGNALS IN REAL TIME, TAKE A FREE
TRIAL TO PAID SERVICES.
The Arora Report is one of the only major global investment newsletters that does not employ a single salesperson—because it does not need to. While competitors rely on high-pressure sales tactics, The Arora Report grows purely through results, with satisfied members recommending it to their family and friends.
Join the service that investors trust the most and recommend to family and friends.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
